(NASDAQ: EXAS) Exact Sciences's forecast annual revenue growth rate of 7.65% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6.06%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.95%.
Exact Sciences's revenue in 2024 is $2,692,328,000.On average, 5 Wall Street analysts forecast EXAS's revenue for 2024 to be $507,485,117,847, with the lowest EXAS revenue forecast at $507,162,714,945, and the highest EXAS revenue forecast at $507,936,333,850. On average, 7 Wall Street analysts forecast EXAS's revenue for 2025 to be $576,591,125,043, with the lowest EXAS revenue forecast at $564,562,276,456, and the highest EXAS revenue forecast at $592,466,229,152.
In 2026, EXAS is forecast to generate $648,874,336,961 in revenue, with the lowest revenue forecast at $638,531,718,479 and the highest revenue forecast at $668,014,371,954.